Capital International Investors Purchases 3,327 Shares of Ascendis Pharma A/S $ASND

Capital International Investors lifted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 0.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,063,943 shares of the biotechnology company’s stock after buying an additional 3,327 shares during the quarter. Capital International Investors’ holdings in Ascendis Pharma A/S were worth $653,355,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. HighVista Strategies LLC lifted its holdings in Ascendis Pharma A/S by 138.1% during the 3rd quarter. HighVista Strategies LLC now owns 7,082 shares of the biotechnology company’s stock valued at $1,408,000 after purchasing an additional 4,108 shares during the last quarter. American Century Companies Inc. lifted its holdings in Ascendis Pharma A/S by 2.6% during the 3rd quarter. American Century Companies Inc. now owns 544,606 shares of the biotechnology company’s stock valued at $108,274,000 after purchasing an additional 13,797 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $15,693,000. Avoro Capital Advisors LLC lifted its holdings in Ascendis Pharma A/S by 2.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after purchasing an additional 130,000 shares during the last quarter. Finally, Fred Alger Management LLC lifted its holdings in Ascendis Pharma A/S by 4,398.1% during the 3rd quarter. Fred Alger Management LLC now owns 170,701 shares of the biotechnology company’s stock valued at $33,937,000 after purchasing an additional 166,906 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND opened at $210.45 on Monday. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $250.74. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The company has a market capitalization of $13.13 billion, a P/E ratio of 24.27 and a beta of 0.39. The stock has a fifty day moving average of $233.16 and a 200-day moving average of $223.65.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. On average, equities analysts expect that Ascendis Pharma A/S will post 12.85 EPS for the current year.

Insiders Place Their Bets

In related news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jean Jacques Bienaime purchased 400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the transaction, the director directly owned 400 shares of the company’s stock, valued at $95,120. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ASND shares. Royal Bank Of Canada raised their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Barclays raised their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Citigroup began coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 target price for the company. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a report on Wednesday, March 4th. Finally, Bank of America lifted their target price on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $295.39.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.